DOS47
Overview
DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells
DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells
DOS47 is designed to offer a means of deriving a therapeutic pharmacological effect by action upon a naturally occurring substance in the body. The technology is based on the principle of using an enzyme to catalyse the metabolism catabolism of and endogenous substrate molecule in order to yield metabolites of therapeutic benefit.
Helix conceived of DOS47 in pursuit of a way to modify the microenvironmental conditions inherent to cancer cells
Specifically cancer generally share a common trait° they exist and propagate under conditions of abnormally low interstitial pH high acidity DOS47 is designed to induce an increase in pH locally at the site of cancerous cells in the body to create an environment inhospitable to their continued growth and survival.
DOS47 is based on the effect of an enzyme called urease acting upon the substrate compound urea
Specifically cancer generally share a common trait° they exist and propagate under conditions of abnormally low interstitial pH high acidity DOS47 is designed to induce an increase in pH locally at the site of cancerous cells in the body to create an environment inhospitable to their continued growth and survival.
Helix believes that DOS47 may have applications both as a monotherapy and in certain combined adjunct chemotherapy regimens.
Helix's granted US patents provide protection for both of these possible therapeutic applications Helix envisions applying its DOS47 technology to multiple different solid tumor types by combining it with cancer specific targeting agents able to localize potent DOS47 therapy to any given tumor target in the body Helix's first DOS47 based targeted therapeutic under development LDOS47 is a potential treatment for inoperable locally advanced recurrent or metastatic non small cell lung cancer NSCLC.
Helix continues to explore opportunities to expand upon its product pipeline with new DOS47based therapeutics
pending the identification of further tumor targeting agents like the lung adenocarcinoma antibody component of LDOS47
Resources
Clinical trials
Pipeline
Our most advanced Tumor Defence Breaker LDOS47 is currently in clinical trials for the treatment of non squamous small cell lung cancer NSCLC The application of LDOS47 in other disease indications is also being considered A second DOS47 candidate known as VDOS47 targets the vascular epithelial growth factor receptor 2 is a preclinical development.
LDOS47 monotherapy NSCLC
LDOS47 VIN¯CIS combo NSCLC
LDOS47 Combo PEM¯CARBO NSCLC
LDOS47 monotherapy NSCLC
LDOS47 monotherapy NSCLC
Pipeline
Our most advanced Tumor Defence Breaker LDOS47 is currently in clinical trials for the treatment of non squamous small cell lung cancer NSCLC The application of LDOS47 in other disease indications is also being considered A second DOS47 candidate known as VDOS47 targets the vascular epithelial growth factor receptor 2 is a preclinical development.
LDOS47 monotherapy NSCLC
LDOS47 VIN¯CIS combo NSCLC
LDOS47 Combo PEM¯CARBO NSCLC
LDOS47 monotherapy NSCLC
LDOS47 monotherapy NSCLC
Pipeline
Our most advanced Tumor Defence Breaker LDOS47 is currently in clinical trials for the treatment of non squamous small cell lung cancer NSCLC The application of LDOS47 in other disease indications is also being considered A second DOS47 candidate known as VDOS47 targets the vascular epithelial growth factor receptor 2 is a preclinical development.
LDOS47 monotherapy NSCLC
LDOS47 VIN¯CIS combo NSCLC
LDOS47 Combo PEM¯CARBO NSCLC
LDOS47 monotherapy NSCLC
LDOS47 monotherapy NSCLC